Form 4: Agios Pharmaceuticals Director Cynthia Smith Reports Stock Transactions

Director Cynthia Smith reports the acquisition and disposal of Agios Pharmaceuticals common stock and restricted stock units on August 11, 2024.

Summary

• On August 11, 2024, Cynthia Smith, a director of Agios Pharmaceuticals, reported transactions involving the company's common stock and restricted stock units.
• Smith acquired 2,302 shares of common stock at a price of $0.
• Concurrently, Smith disposed of 7,992 shares of common stock.
• Smith also acquired 2,302 restricted stock units, each representing a contingent right to receive one share of Agios Pharmaceuticals' common stock.
• Following these transactions, Smith directly owns 2,302 derivative securities.
• The restricted stock units were granted on August 11, 2022, and vest in three equal annual installments beginning August 11, 2023.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director, with no inherent positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.

Key Dates